clofibrate has been researched along with Breast Cancer in 9 studies
angiokapsul: contains clofibrate & insoitolnicotinate
| Excerpt | Relevance | Reference |
|---|---|---|
| "A patient developed severe hypertriglyceridemia while on treatment with Tamoxifen after a mastectomy and with a statin for a lipid disorder." | 7.70 | Tamoxifen and hypertriglyceridemia. ( Jonkers, GH, 1999) |
| "Clofibrate treatment significantly induced PPARα DNA binding activity, and remarkably reduced cyclooxygenase-2/PGE2 and 5-lipoxygenase/LTB4 inflammatory pathways." | 5.43 | Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer. ( Chandran, K; Goswami, S; Sharma-Walia, N, 2016) |
| "It was shown that in patients with breast cancer and cancer of the corpus uteri in the presence of hypercholesterinemia and hypertriglyceridemia the level of blood somatomedin activity would be 3--5 times the control values, being 3." | 5.26 | [Effect of phenformin and miscleron on the blood somatomedin activity level in breast cancer]. ( Bershteĭn, LM; Dil'man, VM; Ostroumova, MN; Vasil'eva, IA, 1980) |
| "A patient developed severe hypertriglyceridemia while on treatment with Tamoxifen after a mastectomy and with a statin for a lipid disorder." | 3.70 | Tamoxifen and hypertriglyceridemia. ( Jonkers, GH, 1999) |
| "The effects of administration of phenformin and clofibrate to 32 breast cancer patients who underwent radical mastectomy and suffered from hormonal metabolic disturbances involving a decline in immunologic response were investigated." | 3.66 | Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. ( Berstein, LM; Buslaeva, VP; Dilman, VM; Fedorov, SN; Kondratjev, VB; Nemirovsky, VS; Nikiforov, YF; Ostroumova, MN; Poroshina, TE; Seleznev, IK; Semiglazov, VF; Tsyrlina, EV; Vasilyeva, IA, 1982) |
| "Some preliminary results of using phenformin and miscleron in 17 breast cancer patients, previously radically operated upon, have been assessed as being characterized by metabolic disturbances associated with the reduced cell immunity level." | 3.66 | [Effect of fenformin and miscleron on the delayed hypersensitivity reaction in breast cancer patients]. ( Bershteĭn, LM; Buslaeva, VP; Kondrat'ev, VB; Ostroumova, MN; Semiglazov, VF, 1980) |
| "Clofibrate treatment significantly induced PPARα DNA binding activity, and remarkably reduced cyclooxygenase-2/PGE2 and 5-lipoxygenase/LTB4 inflammatory pathways." | 1.43 | Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer. ( Chandran, K; Goswami, S; Sharma-Walia, N, 2016) |
| "The promotion of proliferation in breast cancer cell lines following PPARalpha activation was in stark contrast to the effects of PPARgamma-activating ligands that decrease proliferation in human breast cancer cells." | 1.31 | Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231. ( Holman, NA; Lee, WJ; May, FJ; Monteith, GR; Roberts-Thomson, SJ; Robinson, JA; Suchanek, KM, 2002) |
| "It was shown that in patients with breast cancer and cancer of the corpus uteri in the presence of hypercholesterinemia and hypertriglyceridemia the level of blood somatomedin activity would be 3--5 times the control values, being 3." | 1.26 | [Effect of phenformin and miscleron on the blood somatomedin activity level in breast cancer]. ( Bershteĭn, LM; Dil'man, VM; Ostroumova, MN; Vasil'eva, IA, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H | 2 |
| Liu, Y | 1 |
| Yin, Z | 1 |
| Wang, Y | 1 |
| Qian, Y | 1 |
| Chandran, K | 1 |
| Goswami, S | 1 |
| Sharma-Walia, N | 1 |
| Suchanek, KM | 1 |
| May, FJ | 1 |
| Robinson, JA | 1 |
| Lee, WJ | 1 |
| Holman, NA | 1 |
| Monteith, GR | 1 |
| Roberts-Thomson, SJ | 1 |
| Dilman, VM | 2 |
| Berstein, LM | 2 |
| Ostroumova, MN | 4 |
| Fedorov, SN | 1 |
| Poroshina, TE | 2 |
| Tsyrlina, EV | 2 |
| Buslaeva, VP | 2 |
| Semiglazov, VF | 2 |
| Seleznev, IK | 1 |
| Vasilyeva, IA | 1 |
| Kondratjev, VB | 1 |
| Nemirovsky, VS | 1 |
| Nikiforov, YF | 1 |
| Vasil'eva, IA | 1 |
| Bershteĭn, LM | 3 |
| Dil'man, VM | 2 |
| Kondrat'ev, VB | 1 |
| Jonkers, GH | 1 |
| Bobrov, IuF | 1 |
| Kovaleva, IG | 2 |
| Revskoy, SY | 1 |
9 other studies available for clofibrate and Breast Cancer
| Article | Year |
|---|---|
Homologous repair deficiency-associated genes in invasive breast cancer revealed by WGCNA co-expression network analysis and genetic perturbation similarity analysis.
Topics: Breast; Breast Neoplasms; Clofibrate; Female; Humans; Molecular Docking Simulation; Protein Serine-T | 2023 |
Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clofibrate; Female; H | 2016 |
Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231.
Topics: Breast Neoplasms; Cell Division; Clofibrate; Female; Gene Expression Regulation, Neoplastic; Humans; | 2002 |
Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances.
Topics: Age Factors; Body Weight; Breast Neoplasms; Clofibrate; Female; Hormones; Humans; Hypersensitivity, | 1982 |
[Effect of phenformin and miscleron on the blood somatomedin activity level in breast cancer].
Topics: Adult; Aged; Breast Neoplasms; Clofibrate; Female; Humans; Hyperlipidemias; Middle Aged; Phenformin; | 1980 |
[Effect of fenformin and miscleron on the delayed hypersensitivity reaction in breast cancer patients].
Topics: Breast Neoplasms; Clofibrate; Dinitrochlorobenzene; Drug Therapy, Combination; Female; Humans; Hyper | 1980 |
Tamoxifen and hypertriglyceridemia.
Topics: Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Atorvastatin; Breast Neoplasms; Clofibrat | 1999 |
[Correction of endocrine-metabolic disorders in oncologic patients. The effect of biguanides (phenformin and adebita), miskleron and diphenin].
Topics: Adrenal Cortex Hormones; Aged; Biguanides; Blood Glucose; Body Weight; Breast Neoplasms; Buformin; C | 1975 |
Age-dependent metabolic immunodepression and cancer.
Topics: Age Factors; Biguanides; Blood Viscosity; Breast Neoplasms; Cholesterol; Clofibrate; Female; Humans; | 1985 |